New acne gel shows promise in Head-to-Head trial

NCT ID NCT04892706

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 40 times

Summary

This Phase 2 trial tested a new acne gel called IDP-126 against a standard gel (Epiduo Forte) and a placebo gel in 686 people aged 12 and older with moderate to severe acne. Participants applied the gel once daily for 12 weeks. Researchers measured changes in acne lesion counts and overall skin clarity to see if the new gel works better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACNE VULGARIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bausch Site 101

    Manhattan Beach, California, 90266, United States

  • Bausch Site 102

    Tampa, Florida, 33607, United States

  • Bausch Site 103

    Brighton, Massachusetts, 21350, United States

  • Bausch Site 104

    West Palm Beach, Florida, 33401, United States

  • Bausch Site 105

    Boynton Beach, Florida, 33437, United States

  • Bausch Site 106

    San Diego, California, 92123, United States

  • Bausch Site 107

    Gresham, Oregon, 97030, United States

  • Bausch Site 108

    Las Vegas, Nevada, 89148, United States

  • Bausch Site 109

    Dublin, Ohio, 43016, United States

  • Bausch Site 110

    Fremont, California, 94538, United States

  • Bausch Site 111

    Austin, Texas, 78759, United States

  • Bausch Site 112

    San Diego, California, 92123, United States

  • Bausch Site 113

    Saint-Jérôme, Quebec, J7Z 7E2, Canada

  • Bausch Site 114

    Nashville, Tennessee, 37215, United States

  • Bausch Site 115

    Peterborough, Ontario, K91 5K2, Canada

  • Bausch Site 116

    Rockville, Maryland, 20850, United States

  • Bausch Site 117

    Oklahoma City, Oklahoma, 73112, United States

  • Bausch Site 118

    Rogers, Arkansas, 72758, United States

  • Bausch Site 119

    New York, New York, 10022, United States

  • Bausch Site 120

    New Brighton, Minnesota, 55112, United States

  • Bausch Site 121

    Metairie, Louisiana, 70006, United States

  • Bausch Site 122

    West Palm Beach, Florida, 33406, United States

  • Bausch Site 123

    Pflugerville, Texas, 78660, United States

  • Bausch Site 124

    Newnan, Georgia, 30263, United States

  • Bausch Site 125

    Markham, Ontario, L3P 1X3, Canada

  • Bausch Site 126

    Clearwater, Florida, 33761, United States

  • Bausch Site 127

    Boise, Idaho, 83704, United States

  • Bausch Site 128

    San Diego, California, 92123, United States

  • Bausch Site 129

    Louisville, Kentucky, 40241, United States

  • Bausch Site 130

    Waterloo, Ontario, N2J 1C4, Canada

  • Bausch Site 132

    Houston, Texas, 77098, United States

  • Bausch Site 133

    New York, New York, 10075, United States

  • Bausch Site 134

    Bryant, Arkansas, 72022, United States

  • Bausch Site 135

    North Miami Beach, Florida, 33162, United States

  • Bausch Site 136

    Kortrijk, Belgium

  • Bausch Site 137

    Spokane, Washington, 99202, United States

  • Bausch Site 138

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • Bausch Site 139

    Mandeville, Louisiana, 70448, United States

  • Bausch Site 140

    Maldegem, Belgium

  • Bausch Site 141

    Oakville, Ontario, L6J 7W5, Canada

  • Bausch Site 142

    High Point, North Carolina, 27262, United States

  • Bausch Site 143

    Sanford, Florida, 32771, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

IDP-126 gel (a combination acne treatment applied to the skin once daily)

What this could lead to

If it works, this could offer a new once-daily gel option for treating moderate to severe acne.

What could go wrong

This is a Phase 2 trial, so results are still early. The gel may not prove more effective than existing treatments, and side effects like skin irritation are possible.

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.